• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 89 -3 (77) 2025 - Akhmedov F.K., Akhmadzhonova G.M. - PREECLAMPSIA: PATHOMORPHOGENESIS, MODERN APPROACH TO DIAGNOSIS AND TREATMENT

89 -3 (77) 2025 - Akhmedov F.K., Akhmadzhonova G.M. - PREECLAMPSIA: PATHOMORPHOGENESIS, MODERN APPROACH TO DIAGNOSIS AND TREATMENT

PREECLAMPSIA: PATHOMORPHOGENESIS, MODERN APPROACH TO DIAGNOSIS AND TREATMENT

Akhmedov F.K. - Bukhara State Medical Institute named after Abu Ali ibn Sina, Andijan State Medical Institute

Akhmadzhonova G.M. - Bukhara State Medical Institute named after Abu Ali ibn Sina, Andijan State Medical Institute

Asxanova G.B. - Bukhara State Medical Institute named after Abu Ali ibn Sina, Andijan State Medical Institute

Resume

Preeclampsia is a complication of pregnancy and an obstetric factor associated with serious morbidity and mortality of the mother and fetus. The disease is usually manifested by hypertension and, in many cases, proteinuria in the mother, and if the fetus and placenta are not delivered, it is complicated by multi-organ failure, including liver, kidney and brain. The discovery and characterization of antiangiogenic factors in the last decade has further helped to understand the pathophysiology of the disease, and has had a particular impact on the prognosis of the disease and the management of therapeutic measures. The following review analyzes the pathogenic role of antiangiogenic proteins secreted by the placenta in the development of preeclampsia.

Keywords: preeclampsia, pregnancy, risk factor, maternal mortality.

First page

513

Last page

519

For citation:Akhmedov F.K., Akhmadzhonova G.M., Asxanova G.B. - PREECLAMPSIA: PATHOMORPHOGENESIS, MODERN APPROACH TO DIAGNOSIS AND TREATMENT//New Day in Medicine 3(77)2025 513-519 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Klingel R., Gohlen B., Schwarting A., Himmelsbach F., Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther. Apher. Dial 7, 359–364 (2003).
  2. Poston L et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367, 1145–1154 (2006).
  3. Bellamy L., Casas J.P., Hingorani AD Williams DJ Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335, 974 (2007).
  4. Vikse B.E. et al. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med 359, 800–809 (2008).This paper is the first to link pre-eclampsia with future ESRD.
  5. Thebaud B & Abman SH Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am. J. Respir. Crit. Care Med 175, 978–985 (2007).
  6. Vuorela P et al. Amniotic fluid—soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet. Gynecol 95, 353–357 (2000).
  7. ACOG Committee Opinion No. 651 Summary: Menstruation in Girls and Adolescents: Using the Menstrual Cycle as a Vital Sign. Obstet Gynecol. 2015; 126 (6): 1328.
  8. Agents stimulating gonadal function in the human. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1976; 514.
  9. American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 2006; 118(5): 2245–50.
  10. ASRM - Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. Fertil Steril 2021; 116(5): 1255–65.
  11. ASRM - SREI Practice Committee of the American Society for Reproductive Medicine in collaboration with the Practice Committee of the Society for Reproductive Endocrinology and Infertility. Optimizing natural fertility: a committee opinion. Fertil Steril. 2013; 100(3): 631-637.
  12. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004; 18(5): 685-706.
  13. Balen A.H., Morley L.C., Misso M., et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016; 22(6): 687-708.
  14. Bashir S.T., Baerwald A.R., Gastal M.O., Pierson R.A., Gastal E.L. Follicle growth and endocrine dynamics in women with spontaneous luteinized unruptured follicles versus ovulation. Hum Reprod. 2018; 33(6): 1130-1140.
  15. Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014; 20(3): 334-352.
  16. ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update. 2012; 18(5): 586-599.
  17. ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41-47.
  18. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97(1): 28-38 e25.
  19. Fraser I.S., Critchley H.O., Munro M.G., Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007; 87(3): 466-476.
  20. Fraser I.S., Critchley H.O., Munro M.G., Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007; 22(3): 635-643.

    file

    download